Figures & data
Table 1 Results of key clinical trials
Table 2 Side effects observed in key trials involving everolimus and temsirolimus
Table 3 Key messages concerning the BOLERO-2 trial
Table 4 Key messages concerning the BOLERO-3 trial
Table 5 Ongoing trials with everolimus in triple-negative breast cancer
Figure 1 Mechanism of action of different classes of mTOR inhibitors (rapalogs) already approved or under development.
![Figure 1 Mechanism of action of different classes of mTOR inhibitors (rapalogs) already approved or under development.](/cms/asset/63c52d5a-1ed1-4386-9a66-d8c107b6475f/dbct_a_24833916_f0001_c.jpg)
Table 6 Key questions in ongoing clinical trials